Journal article
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS Trial.
- Abstract:
-
Objective
Type 2 diabetes is associated with increased fracture risk, further elevated by treatments such as thiazolidinediones and sodium-glucose co-transporter-2 inhibitors. As data regarding dipeptidyl peptidase-4 inhibitors are mixed, we examined fracture incidence in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Research Design and Methods
We used data from 14,671 TECOS patients randomized double-blind to sitagliptin (n=7332) or place...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Merck and Co., Inc
More from this funder
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Diabetes, Obesity and Metabolism Journal website
- Volume:
- 19
- Issue:
- 1
- Pages:
- 78-86
- Publication date:
- 2016-09-01
- Acceptance date:
- 2016-09-05
- DOI:
- EISSN:
-
1463-1326
- ISSN:
-
1462-8902
- Pmid:
-
27607571
- Source identifiers:
-
641869
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:641869
- UUID:
-
uuid:ce57bb83-a809-495f-979a-0837881a4adc
- Local pid:
- pubs:641869
- Deposit date:
- 2017-05-30
Terms of use
- Copyright holder:
- John Wiley and Sons Ltd
- Copyright date:
- 2016
- Notes:
- © 2016 John Wiley and Sons Ltd
If you are the owner of this record, you can report an update to it here: Report update to this record